<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Pre-transplant predictors of 3-Month survival following liver transplantation for acute liver failure in adult and pediatric patients in Türkiye

Loading...
Thumbnail Image

Departments

Item type:Organizational Unit,

School / College / Institute

Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit

Program

Organization Authors

Co-Authors

Turan, Ilker

Akarca, Ulus Salih

Aladag, Murat

Harputluoglu, Murat

Yilmaz, Sezai

Polat, Kamil Yalcin

Ozcay, Figen

Akarsu, Mesut

Unek, Tarkan

Karasu, Zeki

Date

Language

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

This multicenter retrospective study analyzed 336 patients (236 adults, 100 children) who underwent liver transplantation (LT) for acute liver failure (ALF) between 2002 and 2019 across 14 centers in T & uuml;rkiye. The aim was to evaluate pretransplant factors influencing short-term posttransplant survival. Median MELD and PELD scores were 31 and 30, respectively. The most common ALF etiologies were viral, indeterminate, and drug-induced causes. Living donor liver transplantation (LDLT) was more common in children (86.0%) than adults (57.2%). Mean posttransplant survival was 166 +/- 9 months in children and 117 +/- 6 months in adults. In adults, LDLT significantly improved survival compared to deceased donor LT (DDLT), with survival of 135 vs. 89 months (p=0.0012). Although pediatric LDLT recipients had longer mean survival than DDLT recipients (167 vs. 132 months), this difference was not statistically significant (p=0.5959). Three-month mortality was associated with low albumin and grade 4 hepatic encephalopathy (HE) in children. In adults, independent predictors of early mortality included DDLT, serum sodium >140 mEq/L, MELD >35, pH <7.3, and grade 4 HE. Our data suggest that LDLT may offer a survival advantage, particularly in adults with ALF. Identifying pretransplant risk factors is essential for improving early outcomes and guiding clinical decision-making.

Source

Publisher

Nature Portfolio

Subject

Citation

item.page.haspartof

Source

Scientific Reports

item.page.ispartofseries

item.page.edition

DOI

10.1038/s41598-025-11298-y

item.page.datauri

item.page.link

Rights

CC BY-NC-ND (Attribution-NonCommercial-NoDerivs)

Copyrights Note

Creative Commons license

Except where otherwise noted, this item's license is described as CC BY-NC-ND (Attribution-NonCommercial-NoDerivs)

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
1
Görüntülenme
4
İndirme
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators